查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511978

產後憂鬱症治療藥物的市場規模、佔有率和趨勢分析報告：按類型、治療、給藥途徑、分銷管道、地區和細分市場預測，2024-2030年

Postpartum Depression Drugs Market Size, Share & Trends Analysis Report By Type, Treatment, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

產後憂鬱症治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球產後憂鬱症治療藥物市場預計將達到15.9億美元，預測期內複合年成長率預計為9.63%。

全球懷孕人數的增加主要推動了市場的成長。許多女性在生完孩子後患有產後憂鬱症（PPD），並且在以後的生活中患重度憂鬱症的風險很高。克利夫蘭診所估計，產後憂鬱症是一種常見疾病，影響七分之一的女性產後。因此，政府增加對經歷分娩和患有 PDD 等情緒障礙的婦女的支持預計將在預測期內增加對藥物的需求。

據印度預防與社會醫學協會稱，每年約有 3000 萬婦女懷孕，2700 萬婦女分娩。 2022 年 7 月，印度政府啟動了多項支持孕婦的計劃，包括 Janani Suraksha Yojana (JSY) 和 Janani Shishu Suraksha Karyakaram (JSSK)。根據這些計劃，政府提供免費的懷孕相關治療，包括診斷、藥物和其他用品。因此，像 JSSK 和 JSY 這樣的舉措將幫助女性完成產後憂鬱症治療，同時推動預測期內的市場成長。

推動產後憂鬱症藥物採用的另一個重要因素是醫療保健支出的增加，這有助於改善基礎設施並增加患者使用醫療保健設施的機會。根據 PETERSON-KFF 健康系統追蹤報告，女性每年在懷孕、分娩和產後護理上的花費約為 18,865 美元。這方面差異很大，世界各地區的支出和成本差異很大。增加女性獲得 PPD 治療的機會預計將在未來幾年推動市場成長。

產後憂鬱症治療藥物市場報告亮點

  • 2023年，產後焦慮類別佔市場最大佔有率。這是由於該疾病的高治療率以及已開發國家和新興國家的盛行率不斷上升。
  • 根據治療類型，荷爾蒙療法領域預計在預測期內將以最快的複合年成長率成長。這可以歸因於新荷爾蒙藥物的開發和商業化，以及小型醫院和機構擴大採用它們來治療 PDD。
  • 2023年，根據途徑，口服製劑佔據最大的市佔率。這一優勢是由於全球疾病的盛行率和發病率不斷增加、產品的豐富性以及對新型口服學名藥治療的需求不斷成長。
  • 根據2023年的分銷管道，醫院藥房部門佔據最大的市場佔有率。背後的原因包括醫院治療率、患者相對於其他醫療機構更喜歡在醫院接受PDD治療，以及就診患者數量的增加。
  • 由於先進的醫療基礎設施、不斷上升的疾病盛行率以及有利的法規環境等因素，北美在市場上佔據主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 產後憂鬱症治療藥物市場的變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 產後憂鬱症治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析

第4章產後憂鬱症治療藥物市場：按類型估計和趨勢分析

  • 全球產後憂鬱症治療藥物市場：類型儀表板
  • 全球產後憂鬱症治療藥物市場：類型變異分析
  • 全球產後憂鬱症治療藥物市場：依治療、收益
  • 產後憂鬱症
  • 產後焦慮
  • 產後強迫性精神官能症（OCD）
  • 產後創傷後壓力症候群（PTSD）
  • 產後恐慌症
  • 預防

第5章產後憂鬱症治療藥物市場：依治療方法估算與趨勢分析

  • 全球產後憂鬱症治療藥物市場：治療儀表板
  • 全球產後憂鬱症治療藥物市場：治療變異分析
  • 按治療分類的收益
  • 藥物治療
  • 荷爾蒙療法
  • 其他

第6章 產後憂鬱症治療藥物市場：依給藥途徑估計與趨勢分析

  • 全球產後憂鬱症治療藥物市場：給藥途徑儀表板
  • 全球產後憂鬱症治療藥物市場：給藥途徑變化分析
  • 按途徑的收益
  • 胃腸外的
  • 口服
  • 其他

第7章產後憂鬱症治療藥物市場：依通路估算與趨勢分析

  • 全球產後憂鬱症治療藥物市場：分銷通路儀表板
  • 全球產後憂鬱症治療藥物市場：通路波動分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 其他（網路藥局）

第8章產後憂鬱症治療藥物市場：按治療、治療層級和給藥途徑進行的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • Sage Therapeutics, Inc.
    • Pfizer Inc.
    • Eli Lilly and Company.
    • GSK plc
    • Merck &Co., Inc.
    • Biogen Inc.
    • Bausch Health Companies Inc.
    • Cipla Inc.
    • Novartis AG.
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-319-1

Postpartum Depression Drugs Market Growth & Trends:

The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Postpartum Depression Drugs Market Report Highlights:

  • The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
  • Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
  • In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
  • The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment and Treatment outlook
    • 2.2.2. Route of Administration outlook
    • 2.2.3. Distribution Channel and Availability outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Postpartum Depression Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of postpartum depression
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Postpartum Depression Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Postpartum Depression Drugs Market: Type Dashboard
  • 4.2. Global Postpartum Depression Drugs Market: Type Movement Analysis
  • 4.3. Global Postpartum Depression Drugs Market by Treatment, Revenue
  • 4.4. Postpartum Blues
    • 4.4.1. Postpartum blues market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Postpartum Anxiety
    • 4.5.1. Postpartum anxiety market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Postpartum Obsessive-Compulsive Disorder (OCD)
    • 4.6.1. Postpartum obsessive-compulsive disorder (OCD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Postpartum Post-Traumatic Stress Disorder (PTSD)
    • 4.7.1. Postpartum post-traumatic stress disorder (PTSD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Postpartum Panic Disorder
    • 4.8.1. Postpartum panic disorder market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Preventive
    • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

  • 5.1. Global Postpartum Depression Drugs Market: Treatment Dashboard
  • 5.2. Global Postpartum Depression Drugs Market: Treatment Movement Analysis
  • 5.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
  • 5.4. Pharmacotherapy
    • 5.4.1. Pharmacotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Hormonal Therapy
    • 5.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Postpartum Depression Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Postpartum Depression Drugs Market: Route of Administration Dashboard
  • 6.2. Global Postpartum Depression Drugs Market: Route of Administration Movement Analysis
  • 6.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Postpartum Depression Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global Postpartum Depression Drugs Market: Distribution Channel Dashboard
  • 7.2. Global Postpartum Depression Drugs Market: Distribution Channel Movement Analysis
  • 7.3. Global Postpartum Depression Drugs Market Estimates and Forecasts by Distribution Channel, Revenue (USD Million)
  • 7.4. Hospital Pharmacy
    • 7.4.1. Hospital pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacy
    • 7.5.1. Retail pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Others (Online Pharmacy)
    • 7.6.1. Others (online pharmacy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Postpartum Depression Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key customers
    • 9.2.3. Key company market share analysis, 2023
    • 9.2.4. Sage Therapeutics, Inc.
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. Pfizer Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Eli Lilly and Company.
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. GSK plc
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Merck & Co., Inc.
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Biogen Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Bausch Health Companies Inc.
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Cipla Inc.
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Product benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. Novartis AG.
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Product benchmarking
      • 9.2.12.4. Strategic initiatives
    • 9.2.13. Teva Pharmaceutical Industries Ltd.
      • 9.2.13.1. Company overview
      • 9.2.13.2. Financial performance
      • 9.2.13.3. Product benchmarking
      • 9.2.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 12 Canada postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Canada postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Mexico postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 16 Mexico postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Mexico postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Europe postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 21 Europe postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 22 Europe postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Europe postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Germany postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 25 Germany postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Germany postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Germany postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 UK postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 29 UK postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 UK postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 France postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 33 France postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 34 France postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 France postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Italy postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 37 Italy postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Italy postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Italy postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Spain postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 41 Spain postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Spain postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Spain postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Denmark postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 45 Denmark postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Denmark postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Sweden postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 49 Sweden postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Sweden postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Sweden postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Norway postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 53 Norway postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Norway postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Norway postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 59 Aisa Pacific postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 China postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 62 China postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 China postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 China postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Japan postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 66 Japan postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Japan postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 India postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 70 India postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 India postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 India postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 South Korea postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 74 South Korea postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 75 South Korea postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 South Korea postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Australia postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 78 Australia postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 79 Australia postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Thailand postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 82 Thailand postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Thailand postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 Thailand postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 Latin America postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 87 Latin America postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 88 Latin America postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Latin America postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Brazil postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 91 Brazil postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 92 Brazil postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Brazil postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 95 Argentina postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 96 Argentina postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 MEA postpartum depression drugs market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 100 MEA postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 101 MEA postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 104 South Africa postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 105 South Africa postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 112 UAE postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 113 UAE postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait postpartum depression drugs market, by type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait postpartum depression drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 117 Kuwait postpartum depression drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait postpartum depression drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Postpartum depression drugs market: market outlook
  • Fig. 14 Postpartum depression drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Postpartum depression drugs market driver impact
  • Fig. 18 Postpartum depression drugs market restraint impact
  • Fig. 19 Postpartum depression drugs market: Type movement analysis
  • Fig. 20 Postpartum depression drugs market: Type outlook and key takeaways
  • Fig. 21 Postpartum blues market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Postpartum anxiety market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Postpartum obsessive-compulsive disorder (OCD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Postpartum panic disorder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Postpartum psychosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Postpartum depression drugs market: Treatment movement analysis
  • Fig. 28 Postpartum depression drugs market: Treatment outlook and key takeaways
  • Fig. 29 Pharmacotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Postpartum depression drugs market: Route of administration movement analysis
  • Fig. 33 Postpartum depression drugs market: Route of administration outlook and key takeaways
  • Fig. 34 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Postpartum depression drugs market: Distribution Channel movement analysis
  • Fig. 38 Postpartum depression drugs market: Distribution Channel outlook and key takeaways
  • Fig. 39 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Others (online pharmacy) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Global Postpartum Depression Drugs market: Regional movement analysis
  • Fig. 43 Global Postpartum Depression Drugs market: Regional outlook and key takeaways
  • Fig. 44 Global Postpartum Depression Drugs market share and leading players
  • Fig. 45 North America, by country
  • Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. key country dynamics
  • Fig. 48 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Canada key country dynamics
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico key country dynamics
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UK key country dynamics
  • Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Germany key country dynamics
  • Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 France key country dynamics
  • Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Italy key country dynamics
  • Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Spain key country dynamics
  • Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Denmark key country dynamics
  • Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Sweden key country dynamics
  • Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Norway key country dynamics
  • Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 China key country dynamics
  • Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan key country dynamics
  • Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 India key country dynamics
  • Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Thailand key country dynamics
  • Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Korea key country dynamics
  • Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Australia key country dynamics
  • Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Brazil key country dynamics
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Argentina key country dynamics
  • Fig. 87 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa key country dynamics
  • Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia key country dynamics
  • Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 UAE key country dynamics
  • Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Kuwait key country dynamics
  • Fig. 96 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Market share of key market players- postpartum depression drugs market